Clinical Trials
17 trialsNCT07285044 2026-05-18
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
Phase 2 Recruiting
NCT07224672 2026-03-17
ALANIS
GlaxoSmithKline
Phase 2 Not yet recruiting
NCT04991103 2025-12-31
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
University of Alabama at Birmingham
Phase 2 Recruiting
NCT02924272 2025-03-12
Ixazomib Rollover Study
Takeda
Phase 2 Completed
NCT05066607 2024-03-06
IsAMYP
Intergroupe Francophone du Myelome
Phase 2 Unknown
NCT03959358 2023-07-24
A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders
University Health Network, Toronto
Phase 2 Completed
NCT00224393 2023-05-30
Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis
The Cleveland Clinic
Phase 2 Completed
NCT02207556 2021-07-09
DUAL
Medical College of Wisconsin
Phase 2 Completed
NCT01083316 2020-09-25
Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis
Boston Medical Center
Phase 2 Completed
NCT01222260 2020-03-30
Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis
Columbia University
Phase 2 Completed
NCT01447914 2019-08-28
Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Completed
NCT02632786 2019-04-05
PRONTO
Prothena Biosciences Ltd.
Phase 2 Completed
NCT02791373 2018-04-03
ViGeM
Insel Gruppe AG, University Hospital Bern
Phase 2 Completed
NCT01677286 2017-08-01
Safety and Effect of Doxycycline in Patients With Amyloidosis
Boston University
Phase 2 Completed
NCT01548573 2017-06-14
Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment
University of Iowa
Phase 2 Terminated
NCT01194791 2017-04-25
LENDEXAL
PETHEMA Foundation
Phase 2 Completed
NCT00017680 2008-06-09
Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis
Office of Rare Diseases (ORD)
Phase 2 Completed